← Patent-cliff monitor Loss of exclusivity January 2043 latest FDA-listed patent expiry
Company VERTEX PHARMACEUTICALS INC
Drug detail Brand name ALYFTREK Active ingredient DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR CALCIUM Strength 125MG;50MG;EQ 10MG BASE Dosage form TABLET Route ORAL Modality Small molecule FDA approval December 2024 Marketing status RX
Listed patents Patent Expires Type 12186306 January 2043 use U-4460 11873300 August 2040 substance, product 11066417 February 2039 substance, product 11866450 February 2039 use U-4463 10206877 April 2035 product 11951212 April 2035 product 10058546 July 2033 use U-4218 9012496 July 2033 use U-4097 10047053 May 2032 substance 9512079 May 2032 substance, product 8865902 May 2032 substance, product 9181192 May 2032 substance, product RE50453 July 2031 substance, product 10081621 March 2031 product 11578062 March 2031 product 11564916 August 2029 use U-4466 10646481 August 2029 product 8415387 November 2027 use U-4463 8324242 August 2027 use U-4464 7776905 June 2027 substance, product 7495103 May 2027 substance, product 7645789 May 2027 substance, product 8598181 May 2027 use U-4463 8623905 May 2027 substance, product 10022352 April 2027 product 11639347 April 2027 substance, product 10239867 April 2027 substance, product 9974781 April 2027 product 8754224 December 2026 substance, product 9931334 December 2026 product 8410274 December 2026 product 9670163 December 2026 product 8354427 July 2026 use U-4091
Regulatory exclusivity Code Expires ODE-536 March 2033 ODE-526 December 2031 NCE December 2029
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.